Abstract 1912TiP
Background
nccRCCs are a heterogenous group of rare histologic subtypes, each with distinct biology and response to treatment. There have been few dedicated randomized phase 3 studies in nccRCC, highlighting an urgent unmet need for effective therapies. Sunitinib is the only TKI to have shown a clinical benefit (vs everolimus) in a broad range of histologic subtypes of metastatic nccRCC (Armstrong et al. Lancet Oncol 2016 ). To date, no single agent or combination has shown a significant overall survival (OS) benefit over sunitinib in any nccRCC subtype. Zanzalintinib (XL092), a novel TKI of VEGFR2, MET, AXL, and MER, has shown antitumor and immunomodulatory activity alone, and synergistic antitumor effect with PD1 inhibition, in animal models (Hsu et al. Mol Cancer Ther 2023 ). In a phase 1 study of metastatic solid tumors including RCC, zanzalintinib showed promising clinical activity and a manageable toxicity profile, alone and with an immune checkpoint inhibitor (ICI) (Sharma et al. ESMO 2022 Abs 481P). STELLAR-304 was designed to assess the efficacy and safety of zanzalintinib + nivolumab versus sunitinib in first-line nccRCC (NCT05678673).
Trial design
STELLAR-304 is a global, randomized, open-label study of adults with unresectable/advanced/metastatic nccRCC that is measurable per RECIST v1.1. The trial includes papillary, unclassified, and translocation-associated histologies (sarcomatoid features are allowed); chromophobe, renal medullary carcinoma, or pure collecting duct histology are excluded. Histologies are confirmed by central pathology review. Prior systemic anticancer therapy for advanced or metastatic nccRCC is not permitted; however, 1 prior systemic adjuvant therapy, including ICI and excluding sunitinib, is allowed for completely resected RCC if recurrence occurred ≥6 months after the last adjuvant therapy dose. Patients (N=291) are randomized 2:1 to zanzalintinib + nivolumab or sunitinib alone. The primary endpoints are PFS and ORR per RECIST v1.1 by blinded independent radiology committee. The secondary endpoint is OS; safety will also be assessed. STELLAR-304 is currently recruiting patients in 29 countries in Europe, North and South America, and the Asia-Pacific region.
Clinical trial identification
NCT05678673.
Editorial acknowledgement
Writing and editorial assistance was provided by Alexus Rivas-John, PharmD (Fishawack Communications Inc., part of Fishawack Health, Conshohocken, PA, USA).
Legal entity responsible for the study
Exelixis, Inc.
Funding
Exelixis, Inc.
Disclosure
S.K. Pal: Financial Interests, Personal, Other, Travel Accommodations/Expenses: Ipsen, CRISPR Therapeutics. T.B. Powles: Financial Interests, Institutional, Research Funding: AstraZeneca, Roche, BMS, Exelixis, Ipsen, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai; Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, Mash Up Ltd; Financial Interests, Personal, Other, Travel Accommodations/Expenses: Roche, Pfizer, MSD, AstraZeneca, Ipsen. R. Kanesvaran: Financial Interests, Personal, Advisory Role: MSD, BMS, Eisai, Astellas, J&J, Pfizer, AstraZeneca, Merck; Financial Interests, Personal, Other, Honoraria; Travel Accommodations/Expenses: MSD, Astellas, AZ; Financial Interests, Personal, Other, Honoraria: BMS, Eisai, J&J, Pfizer, Merck. C. Lee: Financial Interests, Institutional, Research Funding: AstraZeneca, BMS, Calithera, Eisai, Exelixis, Merck; Financial Interests, Personal, Advisory Role: Aveo, BMS, Exelixis, Eisai, Merck, Pfizer, EMD Serono, Cardinal Health; Financial Interests, Personal, Other, Honoraria: AiCME, IDEOlogy Health, Intellisphere, Medscape, Research to Practice. Z. Wang: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.; Financial Interests, Personal, Stocks/Shares: Exelixis, Inc.. P. Patel: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.. C. Suarez Rodriguez: Financial Interests, Personal, Advisory Role: Astellas Pharma, Bayer, Hoffmann-La Roche LTD, Ipsen, Merck Sharp and Dohme, Pfizer S.L.U, Sanofi- Aventis; Financial Interests, Institutional, Advisory Role: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1736P - Young adult lung cancer demands more attention in a low-resource area: Bangladesh perspective
Presenter: Muhammad Rafiqul Islam
Session: Poster session 23
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23